Right-to-try law
| Right-to-Try Laws | |
|---|---|
In green: U.S. states with right-to-try laws | |
| Territorial extent | Federal: United States (Right to Try 1.0 only) State (RtT 1.0): 41 states State (RtT 2.0): 17 states |
| Enacted | May 17, 2014 (first state, Colorado) |
| Signed by | Donald Trump (federal) |
| Signed | May 30, 2018 (federal) |
| Introduced by | Sen. Ron Johnson (R–WI) (federal) |
| Related legislation | |
| Expanded access; Individualized Treatments Acts | |
| Status: In force | |
Right-to-try laws broadly are United States state laws and a federal law created with the intent to allow seriously ill patients access to experimental therapies (drugs, biologics, devices). Right-to-try 1.0 (RtT 1.0) allows terminally ill patients access to treatments that have completed Phase I testing but not been approved by the Food and Drug Administration (FDA) across the US, since a federal right-to-try law (RtT 1.0) passed in 2018, extending it across the USA. Right-to-try 2.0 (RtT 2.0) laws, also known as Individualized Treatments Acts, now passed in 17 states, expand patient access in two major ways: they include individuals with non-terminal, rare, or degenerative conditions, and they permit the use of individualized experimental therapies that have not completed Phase I testing.
Before right-to-try laws, patients needed complete FDA approval to use experimental drugs. The framers of these laws argue that this allows for individualized treatments not permitted under the FDA's current regulatory scheme. The value of these laws was questioned on multiple grounds, including that pharmaceutical manufacturers would have no obligation to provide the therapies being sought.